Skip to content
10-Q

Quarterly Report

VYNE THERAPEUTICS INC. VYNE

0001566044-26-000005

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 33.35M sh
Shares Diluted Q1 2026 · Mar 31, 2026 42.77M sh
Shares Diluted Q1 2026 · Mar 31, 2025 42.67M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.08M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$11.46M
Short Term Investments Q1 2026 · Mar 31, 2026 $297K
Short Term Investments Q1 2026 · Dec 31, 2025 $4.98M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $24.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $24.03M
Stockholders Equity Q1 2026 · Mar 31, 2026 $24.64M
Stockholders Equity Q1 2026 · Dec 31, 2025 $27.77M
Stockholders Equity Q1 2026 · Mar 31, 2025 $44.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $52.09M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.24M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.4M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.24M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.4M
Current Assets Q1 2026 · Mar 31, 2026 $25.79M
Current Assets Q1 2026 · Dec 31, 2025 $30.01M
Total Assets Q1 2026 · Mar 31, 2026 $25.87M
Total Assets Q1 2026 · Dec 31, 2025 $30.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.20
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.20
Rd Expense Q1 2026 · Mar 31, 2026 $817K
Rd Expense Q1 2026 · Mar 31, 2025 $6.12M
Net Income Q1 2026 · Mar 31, 2026 −$3.59M
Net Income Q1 2026 · Mar 31, 2025 −$8.61M
Operating Income Q1 2026 · Mar 31, 2026 −$3.82M
Operating Income Q1 2026 · Mar 31, 2025 −$9.2M
Revenue Q1 2026 · Mar 31, 2026 $86K
Revenue Q1 2026 · Mar 31, 2025 $202K